Ionis is a fully integrated biotechnology company pioneering RNA-targeted medicines for serious diseases including rare genetic disorders, neurological conditions, and cardiometabolic diseases, with seven marketed medicines such as SPINRAZA for spinal muscular atrophy and DAWNZERA for hereditary angioedema. The company generates revenue through product sales of its own marketed medicines, royalties from partnered medicines (ranging from mid-single digits to mid-20% of partner sales), and milestone and licensing payments from strategic partnerships with major pharmaceutical companies including Roche, Novartis, GSK, and AstraZeneca. Ionis owns and operates its primary manufacturing facility in California and manages commercialization efforts both independently and through partnerships, leveraging proprietary oligonucleotide technology platforms—including MsPA backbone chemistry and partnerships in gene editing and blood-brain-barrier delivery—to develop treatments for millions of patients worldwide across multiple serious disease categories.